Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia.

Mark J. Levis,Catherine C. Smith,Alexander E. Perl,Gary J. Schiller,Amir T. Fathi,Gail J. Roboz,Eunice S. Wang,Jessica K. Altman,Makoto Ando,Takeaki Suzuki,Ruth Ann Subach,Gary Maier,Timothy Madden,Mary Johansen,Kin-Yin Cheung,Michael R. Kurman

Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia.

2021

Mark J. Levis
Catherine C. Smith
Alexander E. Perl
Gary J. Schiller
Amir T. Fathi
Gail J. Roboz
Eunice S. Wang
Jessica K. Altman
Makoto Ando
Takeaki Suzuki
Ruth Ann Subach
Gary Maier
Timothy Madden
Mary Johansen
Kin-Yin Cheung
Michael R. Kurman

7008Background: FF-10101-01 is a selective and irreversible FMS-like tyrosine kinase 3 (FLT3) inhibitor with potent in vitro activity against FLT3-mutated AML. FF-10101-01 is highly active against ...

Keywords:

Medicine
FLT3 Inhibitor
first in human
Cancer research
Myeloid leukemia
Tyrosine Kinase 3
Refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations